NASDAQ:FDMT 4D Molecular Therapeutics Q4 2024 Earnings Report $12.19 +0.54 (+4.64%) Closing price 08/14/2026 04:00 PM EasternExtended Trading$12.00 -0.19 (-1.56%) As of 08/14/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast 4D Molecular Therapeutics EPS ResultsActual EPS-$0.90Consensus EPS -$0.80Beat/MissMissed by -$0.10One Year Ago EPSN/A4D Molecular Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$2.28 millionBeat/MissN/AYoY Revenue GrowthN/A4D Molecular Therapeutics Announcement DetailsQuarterQ4 2024Date2/28/2025TimeBefore Market OpensConference Call DateFriday, February 28, 2025Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) 4D Molecular Therapeutics Earnings Headlines4DMT Announces New Employment Inducement GrantsAugust 14 at 4:05 PM | globenewswire.com4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming MilestonesAugust 13 at 4:05 PM | globenewswire.comThe dollar just brokeBloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this century — and the consequences for your savings and investments could be severe. President Trump has signed executive order 14241 to initiate the first full reset of the American dollar in 50 years. A new monetary anchor is being established — one that's not gold or crypto, but something far more unexpected that Vladimir Putin once called the key to world leadership. | Porter & Company (Ad)Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Tempus AI, Inc. Class A (TEM)July 22, 2026 | theglobeandmail.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Tempus AI, Inc. Class A (TEM)July 22, 2026 | theglobeandmail.com4D Molecular's one-shot eye therapy delivers two-year winJuly 21, 2026 | msn.comSee More 4D Molecular Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like 4D Molecular Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 4D Molecular Therapeutics and other key companies, straight to your email. Email Address About 4D Molecular Therapeutics4D Molecular Therapeutics (NASDAQ:FDMT), founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches. 4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas. Notable programs target inherited retinal disorders—such as X-linked retinitis pigmentosa and achromatopsia—as well as investigational candidates for neuromuscular and metabolic diseases. By tailoring capsid design to specific tissues, the company seeks to optimize safety and efficacy in patient populations with high unmet medical need. To support its research and development efforts, 4D Molecular Therapeutics engages in collaborations with academic institutions and industry partners in the United States and Europe. The company completed its initial public offering in October 2017, trading on the NASDAQ under the symbol FDMT, and has used the proceeds to advance its clinical and preclinical programs. The company is led by President and Chief Executive Officer John J. Falcon, whose leadership team comprises experienced professionals in gene therapy development, regulatory affairs and commercial strategy. Under Falcon’s guidance, 4D Molecular Therapeutics continues to advance its innovative platform with the goal of delivering transformative treatments to patients suffering from rare genetic disorders.View 4D Molecular Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/10 - 08/14Applied Materials Beat Everything but Wall Street’s Expectations for MarginsBack From Orbit, Intuitive Machines' Share Price Enters the Buy ZoneCerebras Sells Off After Earnings: Is This a Market Disconnection?Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?Sandisk’s Margins Look Like Software. Can They Last?SpaceX’s First Earnings Report Only Made Wall Street More Divided Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
